Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088199 · ClinicalTrials.gov registry record · Phase 3
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT06088199: Active Phase 3 study of Plaque Psoriasis, sponsored by Amgen.
NCT06088199 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Amgen. The registered enrollment target is 51 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06088199, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Conditions Studied
Interventions
- DRUG Apremilast
Study Locations (20)
California
- Avance Clinical Trials - Laguna Niguel
- University of California Irvine - Orange
- MedDerm Associates - San Diego
- Clinical Science Institute - Santa Monica
- California Dermatology Institute - Thousand Oaks
Florida
- Pediatric Skin Research LLC - Coral Gables
- Ciocca Dermatology - Miami
- University of South Florida - Tampa
Arizona
- Affiliated Dermatology - Scottsdale
- Clear Dermatology - Scottsdale
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
- Southern Indiana Clinical Trials - New Albany
Michigan
- Great Lakes Research Group Inc- Sheffield - Bay City
- Henry Ford Medical Center - New Center One - Detroit
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- Johnson Dermatology Clinic - Fort Smith
Illinois
- Endeavor Health Clinical Trials Center - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2026-08-06 |
| Phase | Phase 3 |
What the registry record for NCT06088199 still lists
NCT06088199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Apremilast is the first listed.
NCT06088199 names 20 study sites across 11 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06088199 about?
NCT06088199 is a clinical study titled "A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis". The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
What is the current status of trial NCT06088199?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2023-10-24. Estimated completion is 2026-08-06.
What conditions does trial NCT06088199 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06088199?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT06088199?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06088199 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06088199's enrollment target sits among peer trials
51 37th of 45 higher than 9 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI